Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient
暂无分享,去创建一个
Q. Sun | Yidong Zhou | Ying Xu | B. Pan | R. Yao | Xue-fei Wang | Zhe Wang | Zhixin Hao | Chao Ren | Li Huo